Theraflu® LAR Menthol (Tablets) Instructions for Use
Marketing Authorization Holder
GlaxoSmithKline Healthcare, JSC (Russia)
Manufactured By
Novartis Saglik Gida Ve Tarim Urunleri Sanayi Ve Ticaret A.Ş. (Turkey)
Trademark Owner
GlaxoSmithKline Group of Companies
ATC Code
R02A (Preparations for the treatment of throat diseases)
Active Substances
Lidocaine (Rec.INN registered by WHO)
Cetylpyridinium chloride (Rec.INN registered by WHO)
Dosage Form
| Theraflu® LAR Menthol | Lozenges (menthol) 1 mg+2 mg: 20 pcs. |
Dosage Form, Packaging, and Composition
Lozenges (menthol) white, rectangular, with beveled edges.
| 1 tab. | |
| Cetylpyridinium chloride | 2 mg |
| Lidocaine hydrochloride | 1 mg |
Excipients: black peppermint leaf oil – 0.5 mg, Shimmel peppermint leaf oil – 0.5 mg, levomenthol – 6 mg, acesulfame potassium – 6 mg, corn starch – 55 mg, citric acid monohydrate – 5 mg, macrogol 6000 – 25 mg, microcrystalline cellulose (Avicel PH-105) – 20 mg, magnesium stearate – 2 mg, sorbitol (Karion 3140) – 1107 mg.
10 pcs. – blisters (2) – carton packs.
The secondary packaging may have a first-opening control.
Clinical-Pharmacological Group
Drug with antimicrobial and local anesthetic action for topical use in ENT practice and dentistry
Pharmacotherapeutic Group
Antiseptic + local anesthetic
Pharmacological Action
Combined preparation for topical use, contains an antiseptic agent and a local anesthetic agent.
Cetylpyridinium chloride is an antiseptic from the group of quaternary ammonium compounds, has bactericidal activity against gram-positive and, to a lesser extent, gram-negative bacteria. It alters the permeability of the bacterial cytoplasmic membrane, disrupts the internal oxidative mechanisms of bacterial respiration, which leads to their death. Cetylpyridinium chloride has antifungal and antiviral activity against enveloped viruses.
Lidocaine hydrochloride is a local anesthetic from the amide group, in inflammatory processes it relieves sore throat when swallowing. Lidocaine disrupts the permeability of the cell membrane to sodium ions, which leads to anesthesia as a result of blocking the conduction of nerve impulses.
Pharmacokinetics
Cetylpyridinium chloride is practically not absorbed through the oral mucosa.
Lidocaine hydrochloride is poorly absorbed through the oral mucosa. When taken orally, it is absorbed, undergoing metabolism during the “first pass” through the liver. When taken orally, its bioavailability is about 35%. Metabolites are excreted in the urine, less than 10% of the substance is excreted unchanged.
Indications
Infectious and inflammatory diseases of the oral cavity and throat
- Pharyngitis;
- Laryngitis;
- Catarrhal tonsillitis;
- Stomatitis;
- Ulcerative gingivitis;
- Tonsillitis (as an auxiliary agent).
ICD codes
| ICD-10 code | Indication |
| J02 | Acute pharyngitis |
| J03 | Acute tonsillitis |
| J04 | Acute laryngitis and tracheitis |
| J31 | Chronic rhinitis, nasopharyngitis and pharyngitis |
| J35.0 | Chronic tonsillitis |
| J37 | Chronic laryngitis and laryngotracheitis |
| K05 | Gingivitis and periodontal diseases |
| K12 | Stomatitis and related lesions |
| ICD-11 code | Indication |
| CA02.Z | Acute pharyngitis, unspecified |
| CA03.Z | Acute tonsillitis, unspecified |
| CA05 | Acute laryngitis or tracheitis |
| CA09 | Chronic rhinitis, nasopharyngitis or pharyngitis |
| CA0F.Y | Other specified chronic diseases of the palatine tonsils and adenoids |
| CA0G | Chronic laryngitis or laryngotracheitis |
| DA01.Z | Diseases of the oral mucosa, unspecified |
| DA0B.Z | Gingival diseases, unspecified |
| DA0C.Z | Periodontal diseases, unspecified |
| DA0Z | Diseases or disorders of the orofacial complex, unspecified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
The tablet should be slowly dissolved in the mouth.
The tablet should not be chewed or swallowed. Theraflu® LAR Menthol should not be taken during or immediately before meals.
Adults and children over 12 years 1 tab. every 1-2 hours for acute inflammation and severe pain. For milder conditions – 1 tab. every 2-3 hours. The maximum daily dose is no more than 6 tablets.
Children from 6 to 12 years 1 tab. every 3-4 hours as needed, maximum daily dose – no more than 3 tablets.
Theraflu® LAR Menthol tablets should not be used for more than 5 days in a row. If symptoms persist or are accompanied by high fever, dizziness, or vomiting, it is necessary to stop taking the drug and consult a doctor.
Adverse Reactions
Definition of the frequency of adverse reactions: very common (≥10%); common (≥1%, but ≤10%), uncommon (≥0.1%, but ≤1%), rare (≥0.01%, but ≤0.1%), very rare (≤0.01%).
From the digestive system: rarely – nausea; very rarely – diarrhea.
From the skin and subcutaneous tissues: very rarely – skin rash, itching.
Local reactions rarely – local irritation of the oral and throat mucosa.
Contraindications
- First trimester of pregnancy;
- Breastfeeding period;
- Children under 6 years of age;
- Sucrase/isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption;
- Hypersensitivity to the components of the drug.
With caution: open wounds of the oral mucosa.
Use in Pregnancy and Lactation
The use of the drug Theraflu® LAR Menthol is contraindicated in the first trimester of pregnancy, since the drug crosses the placental barrier. Use in the II-III trimesters of pregnancy is possible under medical supervision, if the expected benefit to the mother outweighs the potential risk to the fetus.
The drug is excreted in breast milk, so it is not recommended for use during breastfeeding.
Pediatric Use
Contraindicated for use in children under 6 years of age.
Special Precautions
The drug should not be taken immediately before meals and simultaneously with milk. Simultaneous intake of the drug with milk and food may reduce the local antiseptic and anesthetic effects.
Alcohol increases the absorption of cetylpyridinium chloride, so the consumption of alcoholic beverages should be avoided while taking the drug.
Cetylpyridinium chloride slows down wound healing.
1 tablet of the drug contains 1107 mg of sorbitol as a sweetener, therefore Theraflu® LAR Menthol should not be taken by patients with congenital fructose intolerance.
Effect on the ability to drive vehicles and mechanisms
No effect.
Overdose
Symptoms with accidental intake of the drug (like other ammonium compounds) in high doses, nausea and vomiting are possible. The lidocaine content in the drug is insignificant and cannot cause serious symptoms of overdose.
Treatment immediately stop taking the drug; it is recommended to drink milk or eat egg white beaten in water.
Drug Interactions
No drug interactions of Theraflu® LAR Menthol have been identified.
Storage Conditions
The drug should be stored out of the reach of children at a temperature not exceeding 30°C (86°F).
Shelf Life
Shelf life – 3 years.
Dispensing Status
The drug is approved for use as an over-the-counter product.
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer
Cavinton Comfort, dispersible pills 10mg 90pcs
Belosalic, ointment, 30g 